Drug discovery, the artwork of figuring out new molecules to develop prescribed drugs, is a notoriously time-consuming and troublesome course of. Conventional strategies, like high-throughput screening, provide an costly scattershot strategy — one that isn’t typically profitable. Nonetheless, a brand new breed of biotech firms are leveraging AI and superior knowledge applied sciences in an try and speed up and streamline the method.
Chai Discovery, an AI startup based in 2024, is one such firm. In slightly over 12 months, its younger co-founders have managed to boost tons of of hundreds of thousands of {dollars} and rally the backing of a few of Silicon Valley’s most influential buyers, making it one of many flashiest companies in a rising business. In December, the corporate completed its Series B, bringing in a further $130 million and a valuation of $1.3 billion.
Final Friday, Chai additionally introduced a partnership with Eli Lilly, a deal by which the pharmaceutical big will use the startup’s software program to assist develop new medicines. Chai’s algorithm, known as Chai-2, is designed to develop antibodies — the proteins essential to battle diseases. The startup has stated it hopes to function a sort of “computer-aided design suite” for molecules.
It’s a vital second for Chai’s explicit discipline. The startup’s deal was introduced shortly earlier than Eli Lilly stated it will additionally collaborate with Nvidia on a $1 billion partnership to create an AI drug discovery lab in San Francisco. This “co-innovation lab,” because it’s being known as, will mix large knowledge, compute sources, and scientific experience, all in an try and speed up the pace of latest medication improvement.
The business isn’t without its detractors. Some business veterans appear to really feel that — given how troublesome conventional drug improvement is — these new applied sciences are unlikely to have a major impact. Nonetheless, for each naysayer, there appear to be simply as many believers.
Elena Viboch, managing director at Common Catalyst — one in all Chai’s major backers — informed TechCrunch that her agency is assured that firms that undertake the startup’s providers will see outcomes. “We imagine the biopharma firms that transfer essentially the most rapidly to associate with firms like Chai would be the first to get molecules into the clinic, and can make medicines that matter,” Viboch stated. “In follow which means partnering in 2026 and by the tip of 2027 seeing first-in-class medicines enter into medical trials.”
Aliza Apple, the top of Lilly’s TuneLab program — which makes use of AI and machine studying to advance drug discovery — additionally expressed confidence in Chai’s product. “By combining Chai’s generative design fashions with Lilly’s deep biologics experience and proprietary knowledge, we intend to push the frontier of how AI can design higher molecules from the outset, with the final word aim to assist speed up the event of revolutionary medicines for sufferers,” she stated.
Techcrunch occasion
San Francisco
|
October 13-15, 2026
Chai might have been based lower than two years in the past, however the startup’s origins started round six years in the past, amid conversations between its co-founders and OpenAI CEO Sam Altman. A kind of founders, Josh Meier, beforehand labored for OpenAI in 2018 on its analysis and engineering staff. After he left the corporate, Altman messaged Meier’s previous faculty buddy, Jack Dent, to ask a couple of potential enterprise alternative. Meier and Dent had initially met in laptop science courses at Harvard however, on the time, Dent was a Stripe engineer (one other firm Altman was an early backer of). Altman requested him if he thought Meier could be open to collaborating on a proteomics startup — that’s, an organization targeted on the examine of proteins.
Altman “messaged me to say that everybody at OpenAI thought extremely of him and requested if I assumed he’d be open to working with them on a proteomics spinout,” Dent stated. Dent informed Altman “in fact,” however there was only one hitch: Meier didn’t really feel just like the know-how was fairly “there” but. The AI tech behind such companies — which leverage highly effective algorithms — was nonetheless a rising discipline and much from the place it wanted to be.
Meier was additionally fairly lifeless set on becoming a member of Fb’s analysis and engineering staff, which is what he would go on to do. At Fb, Meier helped to develop ESM1, the primary transformer protein-language mannequin—an essential precursor to the work Chai is presently doing. After Meier’s time at Fb, he would spend three years at Absci, one other AI biotech agency based mostly round drug creation.
By 2024, Meier and Dent lastly felt ready to deal with the proteomics firm they’d initially mentioned with Altman. “Josh and I reached again out to Sam and informed him we should always choose up that dialog the place we left off—and that we had been beginning Chai collectively,” Dent stated.
OpenAI ended up changing into one in all Chai’s first seed buyers. Meier and Dent truly based Chai — together with their co-founders, Matthew McPartlon and Jacques Boitreaud — whereas understanding of the AI big’s places of work in San Francisco’s Mission neighborhood. “They had been type sufficient to provide us some workplace house,” Dent revealed.
Now, slightly over a 12 months later, as Chai basks within the glow of its newfound partnership with Eli Lilly, Dent says that the important thing to the corporate’s quick development has been assembling a staff of vastly gifted folks. “We actually simply put our heads down and pushed the frontier of what these fashions are able to,” stated Dent. “Each line of code in our codebase is homegrown. We’re not taking LLMs off the shelf which can be within the open supply [ecosystem] and fine-tuning them. These are extremely customized architectures.”
Common Catalyst’s Viboch informed TechCrunch that she felt Chai was able to hit the bottom operating. “There aren’t any basic boundaries to deployment of those fashions in drug discovery,” she stated. “Corporations will nonetheless have to take drug candidates by means of testing and medical trials, however we imagine there’ll be vital benefits to those that undertake these applied sciences — not simply in compressing discovery timelines, but in addition in unlocking courses of medicines which have traditionally been troublesome to develop.”
